1134598-72-3

Upstream product

• 1134598-69-8 2-(3-methoxyphenyl)-3-oxo-3-pyridin-4-yl-propionitrile 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 19924-43-7 3-methoxyphenylacetonitrile 

Downstream Products

• 1134598-74-5 4-[3-methoxy-phenyl]-5-pyridin-4-yl-1H-pyrazol-3-amine 
• 1134598-74-5 4-(3-methoxyphenyl)-3-(pyridin-4-yl)-1H-pyrazol-5-amine 
• 1184103-65-8 3-(3-hydroxyphenyl)-2-pyridin-4-yl-8,9-dihydropyrazolo[1,5-a]quinazolin-6(7H)-one 
• 1184103-64-7 3-(3-methoxyphenyl)-2-pyridin-4-yl-8,9-dihydropyrazolo[1,5-a]quinazolin-6(7H)-one 
• 1184103-22-7 3-(2'-pyridin-4-yl-8',9'-dihydro-7'h-spiro[1,3-dioxolane-2,6'-pyrazolo[1,5-a]quinazolin]-3'-yl)phenol 
• 1184103-19-2 3'-(3-methoxyphenyl)-2'-pyridin-4-yl-8',9'-dihydro-7'H-spiro[1,3-dioxolane-2,6'-pyrazolo[1,5-a]quinazoline] 
• 1184103-77-2 6-allyl-3-(3-methoxyphenyl)-2-pyridin-4-yl-6,7,8,9-tetrahydropyrazolo[1,5-a]quinazolin-6-ol 
• 1184103-36-3 4-bromo-3'-(4-bromo-3-methoxyphenyl)-2'-pyridin-4-yl-4,5,8',9'-tetrahydro-3H,7'h-spiro[furan-2,6'-pyrazolo[1,5-a]quinazoline] 
• 1184103-78-3 3-(4-bromo-3-methoxyphenyl)-6-(2,3-dibromopropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydropyrazolo[1,5-a]quinazolin-6-ol 
• 1134598-80-3 3-(3-amino-5-pyridin-4-yl-1H-pyrazol-4-yl)phenol 
• 1186421-43-1 3-[3-(3-hydroxyphenyl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethylbenzenesulfonamide 
• 1186421-45-3 3-(3-(3-hydroxyphenyl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-N-methylbenzenesulfonamide 
• 1186331-97-4 (3R)-N-{4-[3-(3-methoxyphenyl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]pyridin-2-yl}quinuclidin-3-amine 
• 1186334-43-9 3-(3-methoxyphenyl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7(4H)-one 

Relevant academic research and scientific papers

Discovery of highly potent and selective type I B-Raf kinase inhibitors

A series of pyrazolo[1,5-α]pyrimidine analogs has been prepared and found to be potent and selective B-Raf inhibitors. Molecular modeling suggests they bind to the active conformation of the enzyme.

PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF

Phenylsulfonamide substituted, pyrazolo[1,5-a]pyrimidines are described. The compounds of the invention selectively inhibit Raf kinase activity and are useful for treating disorders associated with Raf kinases. Formula (I)

FUSED TRICYCLIC PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF

Fused, tricyclic pyrazolo{1,5-a]pyrimidine compounds of formula A or of formula B: and pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by certain Raf kinases.

BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF

Compounds of formula A: Formula (1) pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by Raf kinases.